SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023. “We ended 2023 on a strong note, shipping our largest... Read More

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company’s management will discuss the... Read More

SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer. The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from... Read More

SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida. Singular unveiled the G4X™ Spatial Sequencer as a... Read More

SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023. The Company shipped eight G4 instruments in the fourth quarter of 2023. Preliminary unaudited revenue for... Read More

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023. “We shipped five G4 systems in the third quarter, our highest quarterly total... Read More

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company’s management will discuss the results during a conference... Read More

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase. Singular Genomics’ management is scheduled to present on Thursday, September 21, 2023, at 8:30 a.m.... Read More

SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2023. “We made significant advancements across our operations, manufacturing and commercial... Read More

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp... Read More

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the UBS MedTech, Tools and Genomics Summit in Dana Point, California. Singular Genomics’ management is scheduled to participate in a panel discussion titled “Emerging... Read More

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company’s management will discuss the results during a conference... Read More

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, June 13,... Read More

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2023. “We had a productive first quarter, highlighted by shipping three additional G4... Read More

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company’s management will discuss the results during a conference call... Read More

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2022. “2022 was a pivotal year for Singular Genomics. It was a year in... Read More

SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at Cowen’s 43rd Annual Health Care Conference in Boston, Massachusetts. Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, March 7, 2023, at... Read More

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, March 2, 2023. The company’s management will discuss the results during a conference call... Read More

New next-generation sequencing kit maximizes throughput and decreases the cost for single cell experiments Company announces increased quality and throughput specifications of the G4 Sequencing Platform SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today... Read More

SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today released new data from 11 industry-leading genomics partners that validate the performance and versatility of the G4 Sequencing Platform. The datasets are being released during the Advances in Genome... Read More

Demonstrates compatibility of the G4 Sequencing Platform with 10x Genomics Single Cell Applications SAN DIEGO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ Chromium Single... Read More

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited fourth quarter 2022 revenue. The company shipped five G4 instruments through December 31, 2022 and recognized approximately $700 thousand in... Read More

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Singular Genomics’ management is scheduled to present on Thursday, January 12, 2023 at... Read More

SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended September 30, 2022. “We are encouraged with recent progress and are on track to ship G4 units in Q4. We... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the Inaugural Gilmartin Group Emerging Growth Company Showcase has been updated. The new time for the presentation is 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day as previously scheduled,... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Singular Genomics’ management is scheduled to present on Wednesday, August 31, 2022, at 7:30 a.m. Pacific Time / 10:30 a.m.... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended June 30, 2022. “Shipment of the first G4 production system represents another major milestone for Singular Genomics. The G4 offers an unmatched... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced its presentation time at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California has been rescheduled. The new time for the fireside chat is 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time on the same day as... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company’s commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the UBS Genomics 2.0 and MedTech Innovations Summit in Laguna Beach, California. Singular Genomics’ management is scheduled to participate in a fireside chat Thursday, August 11, 2022, at 1:00 p.m. Pacific Time / 4:00... Read More

Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2022 after the market close on Tuesday, August 9, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern... Read More

Max Read kits on the G4 Sequencing Platform will produce up to 4 billion reads per run, enabling high throughput, cost-effective proteomics research Olink continues its pioneering efforts to enable Explore broadly across genomics ecosystems and to democratize next-generation proteomics Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) and Singular Genomics Systems, Inc. (Nasdaq: OMIC) today announced a collaboration to enable... Read More

Singular Genomics Systems Inc. (Nasdaq: OMIC) and TwinStrand Biosciences, Inc. today announced a collaboration to develop highly sensitive next generation sequencing (NGS) solutions for the Singular G4 Sequencing Platform for cutting-edge applications like minimal residual disease (MRD) detection. MRD is a key prognostic indicator that is important for risk stratification, treatment planning and drug development across... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 43 rd Annual Global Healthcare Conference. Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, June 14, 2022, at 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time.... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the quarter ended March 31, 2022. “We are on track to begin shipping G4 instruments to our customers in the second quarter. We are encouraged by the robust external... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the company is collaborating with NVIDIA to validate and optimize the performance of the G4 Sequencing Platform with NVIDIA Clara Parabricks for secondary analysis including alignment and variant calling with over 50 tools for germline... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the formation of its scientific advisory board (SAB). The SAB comprises a distinguished group of academic and industry experts who will advise on the company’s product and service offerings and research and development pipeline. “We are... Read More

Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2022 after the market close on Tuesday, May 10, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2021. “We are pleased with the progression of the G4 launch. There has been robust engagement with potential... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 42 nd Annual Cowen Health Care Conference. Singular Genomics’ management is scheduled to participate in a fireside chat Monday, March 7, 2022, at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.... Read More

Singular Genomics Systems, Inc. , a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Wednesday, March 2, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Dovetail Genomics to validate its proximity ligation kit portfolio, representing the leading methods to unlock access to 3-D genome architecture, with the G4 sequencing platform. The 3-D genome architecture at the... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Twist Bioscience to validate its NGS Target Enrichment Solutions, high-quality target enrichment panels either curated or custom, with the G4 sequencing platform. Twist NGS Target Enrichment Solutions provide an... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Watchmaker Genomics to validate its Watchmaker DNA Library Prep Kits with Fragmentation for the G4 sequencing platform. Precision tools are needed across the entire genomics workflow – from sample input to information... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with New England Biolabs (NEB ® ) to validate its NEBNext kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform. High-quality, high-yield library preparation is a critical first step towards... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Lexogen to demonstrate the G4 sequencing platform’s compatibility with Lexogen’s products for RNA research, specifically the QuantSeq, CORALL and LUTHOR library preparation kits. Transcriptome analysis has long been... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 40 th Annual J.P. Morgan Healthcare Conference. Singular Genomics’ management is scheduled to present virtually on Wednesday, January 12, 2022 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company’s Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the company is collaborating with the Broad Institute of MIT and Harvard to connect the Singular Genomics G4 sequencer to Terra, a data platform co-developed by the Broad Institute, Microsoft and Verily that connects researchers to each... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the commercial launch of the G4, the world’s most powerful benchtop sequencer. The NGS platform features novel high-performance chemistry and advanced engineering to deliver accuracy, flexibility, speed and power for a range of... Read More

Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021. “Early access partnerships for the G4 have been successful, and our partners are achieving accuracy and performance measures at our intended targeted specs. We are grateful... Read More

Singular Genomics Systems, Inc. , a company focused on delivering genomic technologies for the advancement of science and medicine, today announced that it will report financial results for the third quarter of 2021 after the market close on Tuesday, November 9, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested... Read More

Singular Genomics Systems, Inc. , a company focused on delivering genomic technologies for the advancement of science and medicine, today announced it will participate in a fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit, which will be webcast on Wednesday, August 11, 2021 at 3:00 PM Pacific Time. CEO Drew Spaventa and CSO Eli Glezer, founders of Singular Genomics, will present and answer questions about... Read More

Singular Genomics Systems, Inc. , a company focused on delivering genomic technologies for the advancement of science and medicine, today reported its second quarter 2021 financial results and highlighted recent operating and corporate achievements. Investors and the general public are invited to view the company’s quarterly report, filed today on Form 10-Q with the Securities and Exchange Commission ( www.sec.gov ). “We are... Read More

Singular Genomics Systems, Inc. (“Singular Genomics”), a company focused on delivering genomic technologies for the advancement of science and medicine, today announced the closing of its initial public offering of 11,730,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,530,000 additional shares of common stock, at a public offering price of $22.00 per share. All of... Read More